Stay Informed About Key Developments for Our Company

The Latest Updates as They Happen

As a valued partner in our shared success, you should be the first to know what’s happening across our company. The articles and announcements below offer a comprehensive glimpse into the recent developments that shape our business and growth strategies.

News

1 - 10of about 50 News

July 14, 2022

Bayer to sell men’s health product Nebido™ to Grünenthal

June 30, 2022

Not intended for U.S. and UK Media

Kerendia™ (finerenone) approved in China for the treatment of adults with chronic kidney disease associated with type 2 diabetes

June 29, 2022

Not intended for U.S. and UK Media

Bayer opens new Research & Innovation Center in Boston-Cambridge demonstrating its commitment to precision oncology

June 28, 2022

Not intended for U.S. and UK Media

Bayer expands Radiology Business into AI Market with Calantic™ Digital Solutions

June 08, 2022

Bayer’s BlueRock Therapeutics establishes European site for cell therapy innovation

May 23, 2022

Not intended for U.S. and UK Media - Late-breaking data from exploratory post hoc analysis of prespecified pooled analysis FIDELITY presented at Heart Failure 2022 of the Heart Failure Association of the European Society of Cardiology (ESC)

New data support renal and cardiovascular benefits of Kerendia™ (finerenone) in patients with and without history of left ventricular hypertrophy and chronic kidney disease and type 2 diabetes

May 19, 2022

Not intended for U.S. and UK Media

Verquvo™ (vericiguat) approved in China to treat patients with chronic heart failure and reduced ejection fraction

May 10, 2022

First quarter at Bayer:

Very good start to the year - strong sales and earnings growth

May 03, 2022

Not intended for U.S. and UK Media